DRUG
Terlipressin
Terlipressin 1mg IV bolus
Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial.
Status
Unknown
Phase
Phase 4
Enrollment
36
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
Clinical trial to compare the effects of terlipressin and octreotide in the reduction of portal hypertension measured as hepatic venous pressure gradient (HVPG) in patients with liver cirrhosis
Interventions
Treatment arms and agents.
DRUG
Terlipressin
Terlipressin by IV continuous infusion at a rate of 2mg/day (max 4mg/day) during 2 hours
DRUG
Octreotide
Octreotide 50mcg IV bolus plus continuous infusion at a rate of 50mcg/h during 2 hours
Timeline
From registration to results.
First posted
Apr 20, 2020
Study start
Jun 2020
Primary completion
Feb 2022
Study completion
May 2022
Results posted
Not reported
Registry updated
Apr 20, 2020
Outcomes
What the study measures.
Primary outcomes
Change in HVPG
Time frame · 30 minutes, 1 hour and 2 hours
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: 1. Age: 18-75 years old. 2. Liver Cirrhosis 3. Portal hypertension 4. Stable disease in the absence of vasoactive agents 5. Signed informed consent form Exclusion Criteria: * 1\. Patients on medications that can prolong QT interval 2. Patients with HCC not fulfilling Milan criteria for transplant 3. Grade II-IV hepatic encephalopathy 4. GI bleeding in the last 10 days 5. Child-Pugh C above 12 points 6. Bacterial infection in the last 10 days 7. HVPG \<12mmHg 8. Plasma sodium \<130mmol/l 9. Serum creatinine \>2mg/dl 10. Serum bilirubin \>5mg/dl 11. INR\>2.5 12. Uncontrolled cardiovascular disease 13. HIV infection 14. Extra hepatic malignancies 15. Heart failure NYHA Grade III/IV, COPD GOLD\>2 16. Morbid obesity 17. Coronary heart disease or intestinal ischemia 18. Pregnancy or breastfeeding
Study locations
1 registered sites.
Spain. Showing up to 24 locations stored in the fast local snapshot.
Hospital Clinic
Barcelona, Spain
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Terlipressin.
NCT IDStudyPhase / statusEnrollmentUpdated
Intraoperative Continuous Terlipressin Infusion is Associated With Reduced Severe Postoperative Complications After Laparoscopic Hepatectomy: a Prospective Propensity Score-matched Cohort Study
First Affiliated Hospital, Sun Yat-Sen University · Liver Neoplasms · Postoperative Complications
Not applicable
Completed
161
2026-07
Efficacy Of Bovine Colostrum In The Treatment Of Severe Alcohol-Associated Hepatitis: A Randomized Controlled Trial
Dayanand Medical College and Hospital · Alcoholic Hepatitis
Phase 3
Active, not recruiting
174
2026-07
Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation
Beijing Friendship Hospital · Kidney Transplant · Delayed Graft Function
Not applicable
Active, not recruiting
150
2026-07
Interest of in Situ Terlipressin Administration Before the Realisation of Bronchial Biopsy
University Hospital, Rouen · Bronchial Endoscopy
Phase 3
Completed
130
2026-06
Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantation
Istanbul Medipol University Hospital · Liver Transplantation · Portal Hypertension
Not applicable
Recruiting
50
2026-04
ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial.
Assistance Publique - Hôpitaux de Paris · Hemoptysis
Phase 3
Completed
315
2026-04
Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
Noorik Biopharmaceuticals AG · Hepatorenal Syndrome · Liver Cirrhosis
Phase 2
Active, not recruiting
54
2026-04
Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)
Institute of Liver and Biliary Sciences, India · Acute-on-Chronic Liver Failure (ACLF)
Not applicable
Not yet recruiting
56
2026-03
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.